Approval · Notice of Compliance 22806 · 2019
RABEPRAZOLE: Notice of Compliance 22806
Issued October 18, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22806
- Date
- October 18, 2019
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Labelling update to match licensor
- Canadian reference product
- PARIET (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RABEPRAZOLE | Not yet assigned | — |
Medicinal ingredients
- RABEPRAZOLE SODIUM 10 MG per TAB
- RABEPRAZOLE SODIUM 20 MG per TAB